/PRNewswire/ SurvivorNet, the leading digital health platform, today launched a major expansion of its cancer resource information with the addition of an.
/PRNewswire/ SurvivorNet, the leading digital health platform, today launched a major expansion of its cancer resource information with the addition of an.
CRI Immunotherapy Summit Grows Along with Cancer Treatment Prospects pressreleasepoint.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pressreleasepoint.com Daily Mail and Mail on Sunday newspapers.
email article
Adding a targeted agent to chemotherapy failed to improve survival as initial therapy for metastatic urothelial carcinoma, a randomized trial showed.
Median overall survival (OS) was about 14 months with cisplatin-containing chemotherapy when paired with either placebo or the angiogenesis inhibitor bevacizumab (Avastin). Progression-free survival (PFS), a secondary endpoint, favored the bevacizumab arm (8.0 vs 6.7 months).
Grade ≥3 adverse events (AEs) occurred in a similar proportion of patients in each arm, although bevacizumab-related toxicities occurred more often with the addition of the angiogenesis inhibitor, reported Jonathan E. Rosenberg, MD, of Memorial Sloan Kettering Cancer Center in New York City, and colleagues, in the